News and Updates

Although its exact causes are unknown, researchers have uncovered type 1 diabetes risk factors that increase a person's likelihood of developing the condition.

Check out Breakthrough T1D's ADA 2025 coverage of cutting-edge T1D updates in cures, improving lives, and clinical adoption.

Medical Affairs (+Research and Advocacy) Breakthrough T1D’s Medical Affairs program is bridging the gap between access to and adoption of therapies, treatments, drugs, and devices for T1D. To accomplish this goal, the Medical Affairs team is working on healthcare provider (HCP) education, development of clinical care guidelines, and clinical trial education and awareness. Breakthrough T1D’s […]

Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.

Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]

J.J. Spaun’s diagnosis story highlights the importance of screening and monitoring for type 1 diabetes in people of all ages.

The Medical Affairs team is working to ensure the clinical adoption of forthcoming manufactured cell therapies.

This Clinical Trials Awareness Day, we’re exploring lessons from clinical trials and debunking clinical trials misconceptions.

Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how we’re going to make them a reality.

Learn more about GLP-1 therapies and SGLT inhibitors, and how drugs like Ozempic may one day be able to help people with type 1 diabetes.